Navigation Links
FDA Panel to Vote on Drugs to Prevent Prostate Cancer
Date:12/1/2010

WEDNESDAY, Dec. 1 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel is expected to decide Wednesday whether to approve two drugs for the prevention of prostate cancer, the third highest cancer killer of men.

Avodart and Proscar, manufactured by GlaxoSmithKline and Merck, respectively, are already approved to treat enlarged prostates. The drug makers say their research shows the drugs also lower the risk of prostate cancer by more than 20 percent.

FDA regulators have several concerns, the Associated Press reported. For one thing, black men, who are at high risk for the disease, were underrepresented in the clinical trials. "The applicability to African-American men is not known due to marked under-representation," the FDA's online review stated.

Blacks made up just 4 percent of Merck's patients and only 2 percent of Glaxo's patients, according to the AP.

The panel of outside experts assembled by the FDA is also likely to discuss the overall value of preventing low-grade tumors. According to the FDA, more than three-quarters of the tumors the drugs prevent are slow-growing, meaning they are non-aggressive and probably not life-threatening for anyone with a life expectancy of less than 20 years.

But even if the tumors aren't aggressive, Glaxo has said they often involve unnecessary treatment and biopsies, or surgical procedures, to diagnose cancer, that pose risks of their own.

Also, slightly more aggressive tumors were seen in men taking Avodart and Proscar, compared with those taking placebo pills, according to the FDA. But the pharamaceutical companies say the drugs simply make those tumors easier to detect because they shrink the prostate.

The U.S. National Cancer Institute estimates that 217,730 men will be diagnosed with prostate cancer this year and 32,050 men will die of it.

The FDA usually follows the recommendations of its expert panels, although it is not required to do so. If given the go-ahead, Avodart and Proscar would be the first drugs to win FDA approval for prevention of prostate cancer.

More information

For more on prostate cancer, visit the U.S. National Library of Medicine.

-- Margaret Steele

SOURCES: U.S. Food and Drug Administration; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Medicare Panel Endorses Vaccine for Prostate Cancer Patients
2. Teens Should Get Meningitis Booster Shot: CDC Panel
3. Expert Panel Links Popular Bone Drugs to Rare Fracture
4. FDA Panel to Mull Ban on Diet Drug Meridia
5. Experts Support FDA Panels Backing of New Blood Thinner
6. Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds
7. FDA Panel Seems Skeptical Over Key Avandia Data
8. FDA Panel Appears Skeptical Over Key Avandia Data
9. NJIT professor heads panel studying sudden car acceleration
10. FDA Panel Votes Against Approval of Female Viagra
11. FDA Panel Weighs OK of Female Viagra
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... WV (PRWEB) , ... August 18, 2017 , ... ... financial consulting services and asset protection assistance to communities in North-Central West Virginia, ... provide critical services to at-risk boys in the area. , The Chestnut Mountain ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an Indiana-based ... campaigning in support of Campagna Academy in a charity drive to provide for at-risk ... Town of Indiana,” Campagna Academy is a nonprofit organization that has offered critical programs ...
(Date:8/18/2017)... ... 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the memo ... Generation Mindful. To help change the mindset of parents and educators from punitive to ... the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in ...
(Date:8/18/2017)... ... , ... Alcovit, a lime-flavored beverage that rids the body of toxins linked ... now available through Jet.com. , After 25 years of development, the company released ... to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun with ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Our Mountains to Climb: A Journey ... couple that grew stronger together through the faith they shared to overcome struggles in ... the creation of published author, Barbara J. Corcoran, a retired teacher and happily married ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... Directors has approved the payment of a quarterly cash dividend ... The cash dividend of $0.24 per ... to stockholders of record as of the close of business ... to approval of the Board of Directors and may be ...
(Date:8/4/2017)... 3, 2017  Agragen, LLC, a ... the biopharmaceutical, nutraceutical, and aquacultural feed sectors, announces ... lead drug candidates, AGR131.  This drug is designed ... the blood of patients suffering from inflammatory conditions ... disease. Biological ...
(Date:8/2/2017)... -- CaryRx, a next-generation full-service pharmacy, has announced the launch ... the Washington D.C. metropolitan area. CaryRx ... of medications through the convenience of its patient-friendly mobile app. ... one hour to any location in D.C. ... service to Washington D.C. ," says Areo ...
Breaking Medicine Technology: